AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABCL AbCellera Biologics

Trading 01-12 11:11:56 EST

4.49

+0.12

+2.75%

High4.66	Low4.38	Vol2.52M
Open4.63	D1 Closing4.37	Amplitude6.41%
Mkt Cap1.34B	Tradable Cap910.41M	Total Shares299.34M
T/O11.34M	T/O Rate1.24%	Tradable Shares202.75M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ABCL","market":"US","secType":"STK","nameCN":"AbCellera Biologics","latestPrice":4.4903,"timestamp":1768234315420,"preClose":4.37,"halted":0,"volume":2518578,"delay":0,"floatShares":202749853,"shares":299335048,"eps":-0.576766,"marketStatus":"Trading","change":0.1203,"latestTime":"01-12 11:11:56 EST","open":4.63,"high":4.66,"low":4.38,"amount":11337053.970438,"amplitude":0.064073,"askPrice":4.5,"askSize":4445,"bidPrice":4.49,"bidSize":400,"shortable":3,"etf":0,"ttmEps":-0.576766,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1768251600000},"marketStatusCode":2,"adr":0,"listingDate":1607662800000,"exchange":"NASDAQ","adjPreClose":4.37,"preHourTrading":{"tag":"盘前","latestPrice":4.62,"preClose":4.37,"latestTime":"09:29 EST","volume":68995,"amount":319839.0520775,"timestamp":1768228142725},"postHourTrading":{"tag":"盘后","latestPrice":4.54,"preClose":4.37,"latestTime":"19:57 EST","volume":77638,"amount":343926.2318,"timestamp":1768006677225},"volumeRatio":1.771925,"impliedVol":1.07,"impliedVolPercentile":0.6813},"requestUrl":"/m/hq/s/ABCL/wiki","defaultTab":"wiki","newsList":[{"id":"2603544936","title":"AbCellera Doses First Patients in Phase 2 Trial of Menopause Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2603544936","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603544936?lang=en_us&edition=fundamental","pubTime":"2026-01-12 23:58","pubTimestamp":1768233502,"startTime":"0","endTime":"0","summary":"AbCellera Biologics  said Monday the first patients were dosed in the phase 2 portion of its phase 1/2 trial of ABCL635, an experimental antibody to reduce the frequency and severity of vasomotor symptoms, or hot flashes, in postmenopausal women.The second phase is a randomized, double-blind, placebo-controlled study in 80 women and follows an interim review of safety, tolerability and pharmacodynamic data from healthy volunteers in the first phase.AbCellera said the phase 2 enrollment is underway and top-line clinical results for both phases are expected in Q3.Shares of AbCellera Biologics were up 1.5% in recent trading.Price: 4.44, Change: +0.06, Percent Change: +1.49","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2602054612","title":"AbCellera doses first patients in Phase 2 portion of ABCL635 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2602054612","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602054612?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:36","pubTimestamp":1768228583,"startTime":"0","endTime":"0","summary":"AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a po...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abcellera-doses-first-patients-in-phase-2-portion-of-abcl635-trial-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abcellera-doses-first-patients-in-phase-2-portion-of-abcl635-trial-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2602854530","title":"BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2602854530","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602854530?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:11","pubTimestamp":1768227091,"startTime":"0","endTime":"0","summary":"BUZZ-AbCellera rises as it starts mid-stage trial for menopause drug** Shares of drugmaker AbCellera ABCL.O rise 6.2% to $4.64 in premarket trading** Co says it has started dosing patients in a mid-stage trial for ABCL635, its experimental drug aimed at treating hot flashes and other moderate-to-severe symptoms linked to menopause** Drug aims to ease hot flashes and other moderate-to-severe menopause symptoms, per co** Co's ABCL635 offers non-hormonal alternative for women avoiding hormone therapy** Trial will enroll 80 postmenopausal women; results expected in Q3 2026 - ABCL** As of last close, stock up ~17% over the past year  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nL4N3YD12L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2602754543","title":"AbCellera Begins Phase 2 Trial of ABCL635 for Menopausal Vasomotor Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2602754543","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602754543?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:01","pubTimestamp":1768226505,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. has announced the initiation of the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first-in-class non-hormonal treatment for moderate-to-severe vasomotor symptoms associated with menopause. The Phase 2 study is a multicenter, randomized, double-blind, placebo-controlled trial that will evaluate the efficacy of ABCL635 in reducing the frequency and severity of vasomotor symptoms in 80 postmenopausal women. The transition to Phase 2 follows an interim review of safety, tolerability, and pharmacodynamic data from the Phase 1 portion of the study. Top-line clinical results for both phases are expected to be presented in the third quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL53FvFn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2602543479","title":"Abcellera Announces First Patients Dosed in Phase 2 Portion of Its Phase 1/2 Clinical Trial of Abcl635 for the Treatment of Vasomotor Symptoms Due to Menopause","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543479","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543479?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226407,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7R2PZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2602543421","title":"Abcellera Biologics Inc - Anticipates Top-Line Results in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602543421","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602543421?lang=en_us&edition=fundamental","pubTime":"2026-01-12 22:00","pubTimestamp":1768226407,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nTUA7R2PZB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BK4535","BK4121"],"gpt_icon":0},{"id":"2592194443","title":"AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake","url":"https://stock-news.laohu8.com/highlight/detail?id=2592194443","media":"Reuters","labels":["executive","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592194443?lang=en_us&edition=fundamental","pubTime":"2025-12-20 03:36","pubTimestamp":1766172998,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Stephen Quake as a director and beneficial owner of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDLbTNglv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AbCellera Biologics Inc. Files Initial Statement of Beneficial Ownership for Director Stephen Quake","news_tag":"executive,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABCL","BK4121","BK4535"],"gpt_icon":0},{"id":"2592618134","title":"Sector Update: Health Care Stocks Rise Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2592618134","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592618134?lang=en_us&edition=fundamental","pubTime":"2025-12-19 04:55","pubTimestamp":1766091346,"startTime":"0","endTime":"0","summary":"Health care stocks rose late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF  each adding 0.3%.The iShares Biotechnology ETF  fell 0.8%.In corporate news, AbCellera Biologics  shares gained 5.2%. The company will receive $36 million upfront from Bruker  as part of a patent litigation settlement.Irenic Capital Management has built a stake of more than 3% in Integer  and is calling on the company to revamp its board and consider a sale as its shares trade at a discount, The Wall Street Journal reported. Integer shares climbed 5.6%.Eli Lilly  will reduce the prices of its diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada from Dec. 29, The Globe and Mail reported Thursday, citing a note to pharmacies Wednesday night. Eli Lilly shares rose 1.8%.Athira Pharma  shares surged about 66% after it disclosed Thursday that it agreed to acquire the rights for the development and commercialization of lasofoxifene ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2552382215.SGD","IE0009355771.USD","GB00BDT5M118.USD","LU0882574139.USD","LU1064131342.USD","LU0320765059.SGD","BK4121","IE00B7KXQ091.USD","ITGR","LU0128526141.USD","LU0238689110.USD","LU1548497426.USD","LU1169589451.USD","LU2491050154.USD","LU1712237335.SGD","SG9999017495.SGD","IE00BK4W5M84.HKD","LU0943347566.SGD","LU2471134523.USD","LU2552382058.USD","IE0004445015.USD","LU2089984988.USD","LU1057294990.SGD","IE00B775H168.HKD","LU0109394709.USD","LU2361044949.HKD","LU0417517546.SGD","LU2552382132.HKD","BK4082","IE00B4JS1V06.HKD","LU2602419157.SGD","LU0683600562.USD","IE00BKDWB100.SGD","LU1989771016.USD","LU0708995401.HKD","LU0786609619.USD","BK4599","LU2746668974.SGD","BK4581","LU0006306889.USD","LU2360106947.USD","LU2106854487.HKD","LU2237443549.SGD","ABCL","LU1035775433.USD","LU0289739699.SGD","ATHA","LU0820561909.HKD","LU1815336091.USD","LU2087625088.SGD","LU2417539215.USD","SGXZ99366536.SGD","IE00BFSS8Q28.SGD","LU0109391861.USD","LU1093756325.SGD","IE00BFSS7M15.SGD","LU1868836914.USD","LU0203201768.USD","LU1023059063.AUD","SG9999014906.USD","IE00B1BXHZ80.USD","LU2168564495.EUR","XBI","LU2236285917.USD","BK4533","LU0353189680.USD","BK4535","LU0471298777.SGD","IE00BJJMRY28.SGD","LU1720051017.SGD","LU0353189763.USD","BK4516","LU2456880835.USD","LU0757428866.USD","LU1559883803.SGD","LU2361045086.USD","LU1267930730.SGD","LU2750360997.AUD","LU1720051108.HKD","LU0672654240.SGD","LU0266013472.USD","LU0566484027.USD","LU0114720955.EUR","LU0354030511.USD","LU0689472784.USD","LU2168564065.EUR","LU2750360641.GBP","SG9999015986.USD","LU2112291526.USD","XLV","LU2357305700.SGD","LU0456855351.SGD","SG9999015978.USD","SG9999015952.SGD","LU2168564222.USD","LU1988902786.USD","LU2461242641.AUD","SG9999014914.USD","IE00BJJMRX11.SGD","SG9999015945.SGD","LU1169590202.USD","SGXZ51526630.SGD","IE00BJT1NW94.SGD","LU1280957306.USD","LU1804176565.USD","IE0005OL40V9.USD","BK4588","LU1551013342.USD","SG9999001176.SGD","IE00BKPKM429.USD","IE0002141913.USD","LU1069344957.HKD","SG9999001176.USD","LU0097036916.USD","IE00B1XK9C88.USD","LU1093756168.USD","BK4534","LU0316494557.USD","SG9999014898.SGD","LABU","LU0203202063.USD","LU1868837300.USD","LU0256863811.USD","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU0820561818.USD","LU0029874061.USD","LU2746668461.USD","LU1127390331.HKD","LU2211815571.USD","SG9999013999.USD","LU0432979614.USD","LU1366192091.USD","LU2023250504.SGD","LU1868836757.USD","LU0466842654.USD","LU1974910355.USD","LU2468319806.SGD","IE00BN29S564.USD","LU2237443465.HKD","LU0058720904.USD","LU0354030438.USD","LU0079474960.USD","SG9999018857.SGD","SG9999018865.SGD","LU2264538146.SGD","LU2361044865.SGD","LU0471298694.HKD","BK4007","LU0823434583.USD","LU0385154629.USD","LU1623119135.USD","LU0122379950.USD","LU1551013425.SGD","LU1232071149.USD","LU1983299246.USD","LU2168563687.JPY","LU1917777945.USD","LU1868836591.USD","LU2462157665.USD","LU2471134952.CNY","LU2168564149.EUR","LU2237438978.USD","SG9999014880.SGD","LU0061475181.USD","SGXZ31699556.SGD","LU0320765992.SGD","LU1061106388.HKD","LU2265009873.SGD","LU0787776722.HKD","IE0004445239.USD","LU0094547139.USD","IE00BK4W5L77.USD","LU1814569148.SGD","LU0256863902.USD","IE00BWXC8680.SGD","LU0882574055.USD","LU2491049909.HKD","LU1323610961.USD","LU0889565916.HKD","LU2237443895.HKD","LU0198837287.USD","SGXZ57979304.SGD","LU0234572021.USD","LU2237443978.SGD","IE00B4R5TH58.HKD","BK4585","IE00B2B36J28.USD","LU1868837136.USD","LU2108987350.USD","LU2237443382.USD","LU0640476718.USD","LU2324357040.USD","LU2491050071.SGD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU2237443622.USD","LU2471134879.HKD","LU0096364046.USD","LU0823434740.USD","LU0323591593.USD","SGXZ81514606.USD","IE00BJLML261.HKD","LU2471134796.USD","LU2063271972.USD"],"gpt_icon":1},{"id":"2592021989","title":"AbCellera Biologics Says Bruker to Pay $36 Million Upfront in Patent Litigation Settlement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592021989","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592021989?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:46","pubTimestamp":1766069199,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) said Thursday that Bruker (BRKR) will pay it $36 million up front as part of a settlement of patent litigation between the two companies.AbCellera said that as part of the s","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABCL","LU1815336091.USD","BRKR","BK4121","LU0757428866.USD","BK4535"],"gpt_icon":0},{"id":"2592902607","title":"BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902607","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592902607?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:42","pubTimestamp":1766068945,"startTime":"0","endTime":"0","summary":"BRIEF-Abcellera And Bruker Reach Global Settlement Of Patent LitigationDec 18 (Reuters) - Abcellera Biologics Inc ABCL.O:ABCELLERA AND BRUKER REACH GLOBAL SETTLEMENT OF PATENT LITIGATIONABCELLERA BIOL","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","ABCL","BRKR","LU1815336091.USD","BK4121","LU0757428866.USD"],"gpt_icon":0},{"id":"2592901214","title":"Abcellera Biologics Inc - Bruker to Pay Abcellera $36 Mln Upfront and Future Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2592901214","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592901214?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:05","pubTimestamp":1766066747,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4121","LU1815336091.USD","BK4535","ABCL","LU0757428866.USD","BRKR"],"gpt_icon":0},{"id":"2592012949","title":"Abcellera and Bruker Reach Global Settlement of Patent Litigation","url":"https://stock-news.laohu8.com/highlight/detail?id=2592012949","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592012949?lang=en_us&edition=fundamental","pubTime":"2025-12-18 22:05","pubTimestamp":1766066747,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO0QD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ABCL","BRKR","BK4121","BK4535","LU1815336091.USD","LU0757428866.USD"],"gpt_icon":0},{"id":"2590365967","title":"AbCellera to Present at J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2590365967","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590365967?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227918,"startTime":"0","endTime":"0","summary":"AbCellera Biologics Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The live audio webcast of the presentation will be accessible through a link on AbCellera's Investor Relations website, with a replay available after the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via Business Wire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDL4kBb1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4535","ABCL"],"gpt_icon":0},{"id":"2589984264","title":"Assessing AbCellera Biologics (ABCL) Valuation as It Shifts Toward Proprietary Clinical Assets and Phase 1 Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2589984264","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589984264?lang=en_us&edition=fundamental","pubTime":"2025-12-06 13:23","pubTimestamp":1764998616,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (ABCL) just added another twist to its evolving story, as the board moved to replace long time auditor KPMG with Ernst and Young starting with the 2026 fiscal year.\nSee our latest analysis for AbCellera Biologics.\nThe auditor change lands amid a choppy stretch for the stock, with a roughly 24 percent 1 month share price return decline and a still negative 3 year total shareholder return, even though year to date and 1 year total shareholder returns have turned positive as...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-abcl-valuation-as-it-shifts-to","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-abcl-valuation-as-it-shifts-to","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4121","ABCL","BK4535"],"gpt_icon":0},{"id":"2586384267","title":"Director John S. Montalbano Reports Acquisition of AbCellera Biologics Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2586384267","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586384267?lang=en_us&edition=fundamental","pubTime":"2025-11-27 03:58","pubTimestamp":1764187136,"startTime":"0","endTime":"0","summary":"John S. Montalbano, Director at AbCellera Biologics Inc., has reported the acquisition of common shares of the company, according to a recent SEC filing. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5KhWqf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PZZA","BK4121","ABCL","LU0353189680.USD","BK4535","BK4209","LU2065731478.USD","LU2087625088.SGD","LU0353189763.USD"],"gpt_icon":0},{"id":"2586258698","title":"Assessing AbCellera Biologics (NasdaqGS:ABCL) Valuation After New Facility Launch and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2586258698","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586258698?lang=en_us&edition=fundamental","pubTime":"2025-11-26 16:34","pubTimestamp":1764146054,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NasdaqGS:ABCL) recently reported year-over-year revenue growth along with important operational milestones, including activating a clinical manufacturing facility and moving lead drug candidates ABCL635 and ABCL575 into Phase 1 trials. These developments come even as the company reported a wider net loss, largely attributed to higher research and development spending.\nSee our latest analysis for AbCellera Biologics.\nFollowing these recent clinical and operational...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-nasdaqgsabcl-valuation-after-n","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/assessing-abcellera-biologics-nasdaqgsabcl-valuation-after-n","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU2065732104.USD","BK4535","ABCL","PRGS","BK4097","BK4121"],"gpt_icon":0},{"id":"2584132601","title":"Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics","url":"https://stock-news.laohu8.com/highlight/detail?id=2584132601","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584132601?lang=en_us&edition=fundamental","pubTime":"2025-11-20 21:35","pubTimestamp":1763645749,"startTime":"0","endTime":"0","summary":"In a report released yesterday, David Martin PhD from Bloom Burton maintained a Buy rating on AbCellera Biologics, with a price target of $9.00. Da...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/strategic-shift-and-promising-antibody-therapeutics-drive-buy-rating-for-abcellera-biologics-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/strategic-shift-and-promising-antibody-therapeutics-drive-buy-rating-for-abcellera-biologics-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ABCL"],"gpt_icon":0},{"id":"2582375834","title":"Prelude Therapeutics reports third quarter net loss of $19.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582375834","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582375834?lang=en_us&edition=fundamental","pubTime":"2025-11-12 20:02","pubTimestamp":1762948936,"startTime":"0","endTime":"0","summary":"Prelude Therapeutics Inc. reported a net loss of $19.7 million, or $0.26 per share, for the three months ended September 30, 2025, compared to $32.3 million, or $0.43 per share, for the same period in 2024. Non-cash expenses related to share-based payments were $2.4 million, down from $5.9 million in the prior year period. As of September 30, 2025, cash, cash equivalents, restricted cash and marketable securities totaled $58.2 million. The company subsequently received an additional license payment from AbCellera in October 2025 and $60.0 million from Incyte in November 2025. Prelude anticipates that its current funds will support operations into 2027. The company also presented new preclinical data at the European Hematology Association 2025 Congress and will present updated data at the American Society of Hematology Annual Meeting in December 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL81FsCh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","INCY","BK4588","LU2095319765.USD","BK4550","LU0314104364.USD","BK4139","PRLD","LU2210149790.SGD","ABCL","IE00BGHQF748.EUR","NDAQ","BK4532","IE00B3QW5Z07.USD","BK4121","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4535","BK4585","LU2210150020.SGD","BK4112"],"gpt_icon":0},{"id":"1160473051","title":"Stock Track | AbCellera Biologics Plunges 7.20% Following Board Reshuffle and Q3 Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=1160473051","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160473051?lang=en_us&edition=fundamental","pubTime":"2025-11-11 09:06","pubTimestamp":1762823197,"startTime":"0","endTime":"0","summary":"AbCellera Biologics (NASDAQ: ABCL) saw its stock price plummet 7.20% in Monday's trading session, following a series of corporate announcements and its recent Q3 earnings call. The biotechnology...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ABCL"],"gpt_icon":0},{"id":"2582350384","title":"AbCellera Biologics’ Earnings Call: Key Insights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582350384","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582350384?lang=en_us&edition=fundamental","pubTime":"2025-11-11 08:13","pubTimestamp":1762820036,"startTime":"0","endTime":"0","summary":"Abcellera Biologics, Inc. (($ABCL)) has held its Q3 earnings call. Read on for the main highlights of the call. AbCellera Biologics, Inc. recently ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-earnings-call-key-insights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/abcellera-biologics-earnings-call-key-insights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABCL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abcellera.com","stockEarnings":[{"period":"1week","weight":0.2741},{"period":"1month","weight":0.1592},{"period":"3month","weight":-0.2098},{"period":"6month","weight":0.0898},{"period":"1year","weight":0.4422},{"period":"ytd","weight":0.2778}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. It has a research collaboration and license agreement with Eli Lilly and Company; and a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.039273},{"month":2,"riseRate":0,"avgChangeRate":-0.143182},{"month":3,"riseRate":0.2,"avgChangeRate":-0.064544},{"month":4,"riseRate":0.2,"avgChangeRate":-0.104908},{"month":5,"riseRate":0.6,"avgChangeRate":-0.032152},{"month":6,"riseRate":0.4,"avgChangeRate":0.119513},{"month":7,"riseRate":0.6,"avgChangeRate":0.046684},{"month":8,"riseRate":0.4,"avgChangeRate":-0.080936},{"month":9,"riseRate":0.6,"avgChangeRate":0.036664},{"month":10,"riseRate":0.6,"avgChangeRate":0.00539},{"month":11,"riseRate":0.6,"avgChangeRate":-0.007841},{"month":12,"riseRate":0.2,"avgChangeRate":-0.030878}],"exchange":"NASDAQ","name":"AbCellera Biologics","nameEN":"AbCellera Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"AbCellera Biologics,ABCL,AbCellera Biologics股票,AbCellera Biologics股票老虎,AbCellera Biologics股票老虎国际,AbCellera Biologics行情,AbCellera Biologics股票行情,AbCellera Biologics股价,AbCellera Biologics股市,AbCellera Biologics股票价格,AbCellera Biologics股票交易,AbCellera Biologics股票购买,AbCellera Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"AbCellera Biologics(ABCL),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest AbCellera Biologics(ABCL) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction